Clinical Reviews in Allergy & Immunology

, Volume 17, Issue 1–2, pp 213–221 | Cite as

Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma

Clinical pharmacokinetics and safety
  • Louise M. Dubé
  • Linda J. Swanson
  • Walid Awni
Clinical Sciences The Immunobiology of Leukotriene Inhibitors


Theophylline Clinical Review Terfenadine Immunology Volume Zileuton 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568–575.PubMedCrossRefGoogle Scholar
  2. 2.
    Awni WM, Braeckman RA, Granneman GR, Witt G, Dube LM. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600 mg in healthy volunteers. Clin Pharmacokin 1995;29 (Suppl. 2):22–33.Google Scholar
  3. 3.
    Wong SL, Awni WM, Cavanaugh JH, El-Shourbagy T, Locke C, Dube LM. The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokin 1995;29 (Suppl. 2):9–21.Google Scholar
  4. 4.
    Awni WM, Locke CS, Dube LM, Cavanaugh JH. Evaluation of the diurnal variation in the pharmacokinetics of zileuton in normal healthy volunteers. J Clin Pharmacol 1997;37(5):388–398.PubMedGoogle Scholar
  5. 5.
    Machinist JM, Kukulka MJ, Bopp BA. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin Pharmacokin 1995;29 (Suppl. 2):34–41.Google Scholar
  6. 6.
    Awni WM, Cavanaugh JH, Witt G, Granneman GR, Dube LM. The effect of food on the pharmacokinetics of zileuton. Clin Pharmacokin 1995;29(Suppl. 2):62–66.Google Scholar
  7. 7.
    Mayer MD, Kukulka MJ, Amann MT, Machinist JM. Human in vivo and in vitro metabolism of zileuton (abstr). Proceedings of the 7th North American ISSX Meeting 1996;10:315.Google Scholar
  8. 8.
    Braeckman RA, Granneman GR, Locke CS, Machinist JM, Cavanaugh JH, Awni WM. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokin 1995;29(Suppl. 2):42–48.Google Scholar
  9. 9.
    Awni WM, Cohn J, Lanni C, Dube L, Leutrol Study Group. The relationship of zileuton pharmacokinetics and pharmacodynamics as assessed by inhibition of leukotriene B4 biosynthesis and improvement in pulmonary function in patients with moderate asthma (abstr). Eur Resp J 1994;7(Suppl 18):152s.Google Scholar
  10. 10.
    Awni WM, Granneman GR, Locke C, Brandwein SR, Dube LM. Population pharmacokinetics of zileuton, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. Eur J Clin Pharm 1995;148:155–160.Google Scholar
  11. 11.
    Coleman D, Awni W, Kelly HW, McWilliams BC, Bialek-Smith S, Dube L. Initial pharmacokinetics evaluation of zileuton in asthmatic children (abstr). Am J Resp Crit Care Med 1995;151(4, Suppl):A377.Google Scholar
  12. 12.
    Awni WM, Wong W, Chu S-Y, Patterson K, Hansen R, Machinist JM, Drajesk J, Keane WF, Halstenson CE. Pharmacokinetics of zileuton and its metabolites in subjects with renal impairment. J Clin Pharmacol 1997;37(5):395–404.PubMedGoogle Scholar
  13. 13.
    Awni W, Cao G, Locke C. Population modeling of leukotriene B4 (LTB4) inhibition by zileuton in asthmatic children (abstr). Pharm Res 1995;12(Suppl 9):S362.Google Scholar
  14. 14.
    Wong SL, Locke C, Dube L, Granneman GR, Awni WM. Meta-analysis of the pharmacodynamic relationship between the ex vivo LTB4 inhibition in whole blood and zileuton plasma concentrations from Phase I studies in normal volunteers using NONMEM approach (abstr). Pharm Res 1994;11(Suppl 10):S-434.Google Scholar
  15. 15.
    Machinist JM, Mayer MD, Shei MS, Ferrero JL, Rodrigues AD. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Meta Dispo 1995;23:1163–1174.Google Scholar
  16. 16.
    Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokin 1995;29(Suppl 2):77–83.Google Scholar
  17. 17.
    Sarker MA, Jackson BJ. Theophylline N-demethylations as probes for P450 1A1 and P450 1A2. Drug Meta Dispo 1994;22:827–834.Google Scholar
  18. 18.
    Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokin 1995;29(Suppl 2):67–76.Google Scholar
  19. 19.
    Rettie AK, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin drug interaction. Chem Res Toxicol 1992;5:54–59.PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of the human CYP isoforms involved in the metabolism of propranolol enantiomers— N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharm 1995;39:421–431.Google Scholar
  21. 21.
    Awni WM, Cavanaugh JH, Leese P, Kasier JF, Cao G, Locke CS, Dube LM. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharm 1997;52(1):49–54.CrossRefGoogle Scholar
  22. 22.
    Yun C-H, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Drug Metab Dispos 1993;21:403–407.PubMedGoogle Scholar
  23. 23.
    Awni WM, Cavanaugh JH, Tzeng T-B, Witt G, Granneman GR, Dube LM. Pharmacokinetic interactions between zileuton and prednisone. Clin Pharmacokin 1995;29(Suppl 2):105–111.Google Scholar
  24. 24.
    Awni WM, Hussein Z, Cavanaugh JH, Granneman GR, Dube LM. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Clin Pharmacokin 1995;29(Suppl 2):92–97.CrossRefGoogle Scholar
  25. 25.
    Samara E, Cavanaugh JH, Mukherjee D, Granneman GR. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Clin Pharmacokin 1995;29(Suppl 2):84–91.Google Scholar
  26. 26.
    Awni WM, Braeckman RA, Locke CS, Dube LM, Granneman GR. The influence of multiple oral doses of zileuton on the steady state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clin Pharmacokin 1995;29(Suppl 2):98–104.Google Scholar
  27. 27.
    Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, Dube LM. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers. Clin Pharmacokin 1995;29(Suppl 2):112–124.CrossRefGoogle Scholar
  28. 28.
    Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993;119:1059–1066.PubMedGoogle Scholar
  29. 29.
    Israel E, Cohn J, Dube L, Drazen JM, Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma, a randomized controlled trial. JAMA 1996;275:931–936.PubMedCrossRefGoogle Scholar
  30. 30.
    Liu MC, Dube LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996;98:859–871.PubMedCrossRefGoogle Scholar
  31. 31.
    Zyflo Package Insert, 1996.Google Scholar
  32. 32.
    Lazarus SC, Lee TM, Wright S, Sarocco P, Rosenstein L, Bialek-Smith S, Dube L, Zileuton Safety Trial Study Group. Secondary outcomes analysis of zileuton plus usual care vs. usual care alone in the treatment of patients with asthma. Annual meeting of the American College of Allergy, Asthma, and Immunology. Boston, MA. November 8–13, 1996. Abstract 50.Google Scholar
  33. 33.
    Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER (eds.): Disease of the liver, 7th ed. Philadelphia: JB Lippincott.Google Scholar
  34. 34.
    Zimmermam HJ. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. New York: Appleton Century Crofts, 1978.Google Scholar
  35. 35.
    Lewis JH. Hepatic toxicity of nonsteroidal antiinflammatory drugs. Clin Pharm 1984;3:128–138.PubMedGoogle Scholar
  36. 36.
    Tobert J, Shear CL, Chramos AN, Mantell GE. Clinical experience with lovostatin. Am J Cardiol 1990;65:23F.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc 1999

Authors and Affiliations

  • Louise M. Dubé
    • 1
  • Linda J. Swanson
    • 1
  • Walid Awni
    • 1
  1. 1.Abbott LaboratoriesAbbott Park

Personalised recommendations